Webinar: GLP-1 Drug Update: The Backlash and The Future

Wednesday, July 16, 20251:00p.m. Eastern/10:00 a.m. Pacific - 90-minutes Overview When the Food and Drug Administration approved longtime diabetes drug Wegovy for weight loss in 2021, the floodgates opened. Millions of Americans sought prescriptions for Wegovy and other GLP-1 medications since approved for weight loss. Despite costing $1,000 a month or more, the drugs were considered a key toward reducing the incidence of heart disease, diabetes and other chronic conditions associated with obesity. Then came the backlash. The Medicare program said it would not cover GLP-1s for weight loss due to its cost. Ditto for California’s Medicaid program. Cigna created a new division just to manage the costs of GLP-1s. Regional plans such as Independence Blue Cross in Pennsylvania have put bans into place. And the Food and Drug Administration barred the production of lower-cost compounded GLP-1s. But while the near-term future of GLP-1s for weight loss seems to have clouded, possibilities over t